Acadia Pharmaceuticals (ACAD) Net Cash Flow Growth (1y) (2011 - 2026)
Acadia Pharmaceuticals (ACAD) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 53.46% |
| 10 | Acadia Pharmaceuticals | 4.38 Bn | 3.53 Bn | 243.27 Mn | 202.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202.56% |
| Dec 31, 2025 | -149.81% |
| Sep 30, 2025 | 123.01% |
| Jun 30, 2025 | 232.61% |
| Mar 31, 2025 | -733.51% |
| Dec 31, 2024 | 81.82% |
| Sep 30, 2024 | -56.63% |
| Jun 30, 2024 | 84.71% |
| Mar 31, 2024 | -90.86% |
| Dec 31, 2023 | 326.26% |
| Sep 30, 2023 | -180.62% |
| Jun 30, 2023 | -177.46% |
| Mar 31, 2023 | 206.27% |
| Dec 31, 2022 | -175.74% |
| Sep 30, 2022 | 108.71% |
| Jun 30, 2022 | -73.44% |
| Mar 31, 2022 | 366.79% |
| Dec 31, 2021 | 141.79% |
| Sep 30, 2021 | -221.42% |
| Jun 30, 2021 | -127.32% |